Latest Content

Genetic ancestry was linked to differences in colorectal cancer (CRC) burden and age-specific risk, with implications for screening.

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA.

Rising premiums and out-of-pocket costs top Americans' health care concerns across party lines, a Commonwealth Fund survey finds.

Although topical delgocitinib matched injectable dupilumab for CHE, real-world adherence could determine whether that holds outside clinical trials.

It also flagged persistent gaps in biomarker testing and the limits of cross-trial comparisons for treatment selection.

A narrative review links IL-17 signaling to metabolic syndrome and cardiovascular risk in psoriasis, though hard-outcome trial data remain limited.

After CAR T-cell therapy relapse in mantle cell lymphoma, an antibody drug conjugate regimen adapted from DLBCL shows durable remission.

Employers with complete claims data access deploy more cost-containment strategies as health care costs rise and employers seek greater PBM transparency.

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.